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Background/aim: Ultrasonography and fine-needle aspiration biopsy are frequently used to diagnose thyroid cancer. However,
supportive data might be required in case of diagnostic difficulty. This study investigated whether there is a relationship between thiol/
disulphide homeostasis and cytological and histopathological diagnosis of thyroid nodules.
Materials and methods: The patient group consisted of 81 individuals with euthyroid nodular (single/multiple) goiter scheduled
for thyroidectomy, and the control group consisted of 28 age- and sex-matched healthy volunteers who had no thyroid nodule on
ultrasonographic evaluation. All participants were selected among the admissions to the study clinic between June 2017 and June
2018, and venous blood samples were collected. The samples of the patients were taken before surgery. Thiol and disulphide levels were
analysed with the automated spectrophotometric method.
Results: The mean age of the patient group was 45.66 ± 10.45 years, and the mean age of the control group was 43.53 ± 11.49 years (p =
0.365). The increasing Bethesda categories were positively correlated with the disulphide level (r = 0.281, p = 0.011), disulphide/native
thiol ratio (r = 0.241, p = 0.030) and disulphide/total thiol ratio (r = 0.250, p = 0.024). Disulphide/native thiol ratio and disulphide/
total thiol ratio were significantly higher in the histopathologically malignant (euthyroid nodular goiter but final pathology reported
malignant) compared to histopathologically benign (euthyroid nodular goiter but final pathology reported benign) (p = 0.012; p = 0.007,
respectively) and control groups (p = 0.006; p = 0.004, respectively), but no significant difference was found in these ratios between
benign and control group (p = 0.711; p = 0.749, respectively).
Conclusion: Oxidative stress parameters were significantly higher in thyroid cancer. A positive correlation was detected between
Bethesda categories with increased risk of malignancy and the disulphide/native thiol ratio and the disulphide/total thiol ratio.
Key words: Thyroid cancer, oxidative stress, Bethesda, thiol/disulphide

1. Introduction
The frequency of detection of thyroid nodules is gradually
increasing with the widespread use of ultrasonography
[1,2]. Thyroid nodule size and malignancy risk are
important parameters that should be evaluated during
the management of thyroid nodules in euthyroid patients
[3]. The gold standard method for the differentiation of
benign and malignant nodules is fine-needle aspiration
biopsy (FNAB) [3]. The cytological specimen obtained
by biopsy is generally classified according to the Bethesda
classification system [4]. Accordingly, there are six

groups; nondiagnostic, benign, atypia of undetermined
significance/follicular lesion of undetermined significance
(AUS/FLUS), follicular neoplasia/suspicious for follicular
neoplasia (FN/SFN), suspicious for malignancy (SM),
and malignant [5]. The cytology result obtained upon this
classification is combined with ultrasonography data, and
a follow-up plan is developed. Particularly in nodules with
indeterminate results, molecular markers such as B-Raf
proto-oncogene mutation analysis may also be helpful in
deciding the management [3]. However, many clinicians
need further supportive data to manage euthyroid
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multinodular goiter. Thiols constitute a large part of
antioxidants and provide defence against reactive oxygen
species (ROS) through their role in redox homeostasis [6].
Thiols have the sulfhydryl group and may enter the oxidation
reaction to form disulphide bonds [6]. Dynamic thioldisulphide homeostasis reverses thiol oxidation in proteins
and represents thiol and disulphide levels [6]. Dynamic
thiol-disulphide plays a crucial role in many events such as
homeostasis, antioxidant protection, detoxification, signal
transduction, apoptosis, and regulation of enzymatic
activity [6,7]. There is evidence that abnormal thioldisulphide homeostasis plays a role in the pathogenesis
of diabetes, cancer, rheumatic diseases, chronic kidney
disease, and neurodegenerative diseases [8-13]. Therefore,
determining dynamic thiol-disulphide homeostasis may
provide information about various biochemical processes
[6]. Only a small part of the total thiol in the organism
consists of low molecular weight thiols. In plasma, total
thiols are lower than in cells, and the predominant thiol is
human serum albumin [14]. In 2014, Erel and Neşelioğlu
developed a new automated spectrophotometric method
in which two elements can be measured separately, thus
representing both sides of the balance simultaneously [6].
Using this method, we aimed to determine whether there
is a relationship between cytological findings and oxidative
stress, and we investigated the role of oxidative stress in the
differentiation of benign and malignant thyroid nodules.
2. Materials and methods
2.1. Participants
This study included 81 patients diagnosed with
euthyroid nodular (single/multiple) goiter scheduled
for thyroidectomy. These patients were selected after the
thyroid surgery multidisciplinary council, in which an
average of 30 thyroid patients were evaluated every week.
The process was completed between June 2017 and June
2018. Thyroidectomy indications were the coexistence
of giant nodule, malignant, SM, FN/SFN, AUS/FLUS, or
persistent nondiagnostic cytology, and patients’ preference.
Patients with hypothyroidism, hyperthyroidism, diabetes
mellitus, cardiovascular diseases, cerebrovascular diseases,
chronic kidney diseases, chronic liver diseases, rheumatic
diseases, and malignancy were excluded from the study
[15]. Patients on lipid-lowering drugs, patients who use
alcohol, and smokers were excluded as well. Twenty-eight
age- and sex-matched healthy volunteers who had no
thyroid nodule on ultrasonographic evaluation formed
the control group. Exclusion criteria were also applied to
this group. Twelve-hour fasting venous blood samples of
all the participants who met the inclusion criteria were
collected between the study dates. The samples of the
patient group were taken immediately after the council,
before thyroidectomy. Preoperative thyroid functions

[serum thyrotropin (TSH), free triiodothyronine (fT3),
free thyroxine (fT4)], antithyroid peroxidase antibody
(anti-TPOAb), antithyroglobulin antibody (antiTGAb), cytology results, and histopathology results
(malignant/benign) were obtained from medical records.
Serum TSH, fT3, and fT4 levels were measured using
chemiluminescence methods (Immulite 2000, Diagnostic
Products Corp., Los Angeles, California and UniCel DXI
800, Beckman Coulter, Brea, California). Normal ranges
for TSH, fT3, and fT4 were 0.27–4.2 uIU/mL, 1.57–4.71
pg/mL and 0.61–1.12 ng/dL, respectively. The study was
conducted following the 2013 Brazilian version of the
Helsinki Declaration and was approved by the Local Ethics
Research Committee.
2.2. Thiol/disulphide homeostasis
Venous blood samples from the patients and healthy
controls were collected after 12 h of fasting and put in
EDTA tubes. Plasma samples were separated from cells
by centrifugation at 1500 × g for 10 min. Samples were
run immediately or stored at –80 °C. During the thiol/
disulphide homeostasis tests, the reducible disulphide
bonds were first reduced to form free functional thiol
groups. Formaldehyde was used to remove unused and
consumed sodium borohydride. Total thiol (–SH+–
S–S) and native thiol (–SH) levels in the samples were
measured using Ellman’s and modified Ellman’s reagent
[16]. The natural thiol content was subtracted from the
total thiol content, and half of this difference gave the
amount of dynamic disulphide bonds (–S – S–). Using
these parameters, disulphide/native thiol ratios (–S – S–)
× 100/(– SH), disulphide/total thiol ratios (–S – S–) × 100/
(- SH+–S – S–) and native thiol/total thiol ratios ( –SH) ×
100/(- SH+– S – S–) ratios were calculated.
2.3. Ultrasonography
Experienced endocrinologists performed ultrasonography
(DO, RE) using Esaote color Doppler ultrasonography
device (Model 796 FDII; MAG Technology Co. Ltd., YungHo City, Taipei, Taiwan) and a superficial probe (Model
LA523 13-4 5.5-12.5 Mhz).
2.4. Fine-needle aspiration biopsy and cytology
FNAB was performed under ultrasonography (Logic Pro
200 GE and 7.5 MHz probes; Kyunggigo, Korea) guidance
with a 27-gauge needle and a 20-mL syringe. Samples
were air-dried and stained with Giemsa stain. Bethesda
classification system was used for cytological diagnosis
[4]. In patients with multiple nodules, the nodule carrying
the highest risk of malignancy according to the Bethesda
classification was taken into consideration. In this study,
malignancy risk was coded as ordinal data from 1 to 6
(1 = benign, 2 = nondiagnostic, 3 = AUS/FLUS, 4 = FN/
SFN, 5 = SM, 6 = malignant) according to cytology results.
Malignancy risk was accepted to increase as the Bethesda
category went from 1 to 6.
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2.5. Histopathology
The histopathological evaluation was made according to
the 2004 World Health Organization criteria [17].
2.6. Statistical analysis
All statistical analyses were performed with the SPSS
15.0 software package (SPSS, Inc., Chicago, Illinois).
Descriptive statistics for the continuous variables were
expressed as mean ± SD or median (range), and categorical
variables were noted as numerics and percentages (%).
Student’s t-test was used to compare independent groups
with normal distribution, and the Mann–Whitney U test
was used for those that are not normally distributed. Chisquare was used to compare categorical variables. The
Kruskal–Wallis test was used when comparing three or
more independent groups without normally distributed
data, and the one-way ANOVA test was used for normally
distributed data. Post hoc Dunn’s test with Bonferroni
correction was performed. p < 0.05 was considered to be
statistically significant. Spearman correlation test was used
to present the relationship between malignancy risk and
thiol/disulphide homeostasis.
3. Results
There were 57 women (70.4%) and 24 men (29.6%) in
the patient group (n = 81), and 19 women (67.9%) and
9 men (32.1%) in the control group (p = 0.803). The
mean age of the patient group was 45.66 ± 10.45 (18–65)
years, and the mean age of the control group was 43.53 ±
11.49 (24–64) years (p = 0.365). There was no difference
between the groups regarding body mass index, TSH,

fT3, fT4 (Table-1). Anti-TG was positive in 19.8% of
the patients, and anti-TPO was positive in 16% of the
patients; however, there was no significant difference
between positive autoantibody patients vs. whole negative
population for thiol/disulphide ratio (p > 0.05). According
to the ultrasonography findings, solitary nodules were
detected in 15 (18.5%) patients, while multinodular goiter
was detected in 66 (81.5%) patients. Cytological diagnosis
was nondiagnostic (recurrent) in 23 (28.4%), benign in 17
(21.0%), AUS/FLUS (recurrent) in 20 (24.7%), FN/SFN
in 5 (6.2%), SM in 8 (9.9%), and malignant in 8 (9.9%)
patients. Native thiol, total thiol, and disulphide levels,
disulphide/native thiol, disulphide/total thiol, and native
thiol/total thiol ratios according to cytological results
are given in Table 2. There was no significant difference
in terms of these parameters between cytology groups.
Significant positive correlations were detected between
increasing risk of malignancy according to cytology and
disulphide (r = 0.281, p = 0.011), disulphide/native thiol
(r = 0.241, p = 0.030) and disulphide/total thiol (r = 0.250
p = 0.024) (Table 3). On the other hand, there was no
significant correlation between age, BMI, albumin level of
patients, and their oxidative stress parameters (p > 0.05).
Thyroidectomy was performed in 69 (85.2%) out of 81
patients. Histopathological diagnosis was benign in 34
(49.3%) and malignant in 35 (50.7%) patients. There was
papillary thyroid cancer in 32 (91.5%) patients and tumour
with uncertain malignant potential in 3 (8.5%) patients. The
mean age was 45.8 ± 11.0 years the malignant patients and
46.3 ± 11.0 years in the benign group. In addition, 65.7%

Table 1. Demographical features and laboratory findings of the study population.
Variables

Euthyroid nodular goiter (n=81)

Control (n = 28)

p-value

Sex, n (%)
female
male

57 (70.4%)
24 (29.6%)

19 (67.9%)
9 (32.1%)

0.803

Age (years)

45.66 ± 10.45

43.53 ± 11.49

0.365

BMI (kg/m2)

28.49 ± 3.95

26.96 ± 4.78

0.099

TSH (μIU/mL)

1.72 ± 0.87

1.78 ± 0.58

0.706

fT4 (ng/dL)

1.28 ± 0.17

1.23 ± 0.18

0.295

fT3 (ng/dL)

3.26 ± 0.46

3.37 ± 0.35

0.249

Anti-TG positivity

16 (19.8%)

0 (%)

-

Anti-TPO positivity

13 (16.0%)

0 (%)

-

Total Bilirubin (mg/dL)

0.60 ± 0.49

0.58 ± 0.29

0.298

Albumin (g/dL)

4.61 ± 0.30

4.80 ± 0.35

0.001

CRP (mg/L)

1.48 ± 2.56

1.39 ± 2.31

0.965

BMI: Body mass index, TSH: Serum thyrotropin, fT4: Free thyroxine, fT3: Free triiodothyronine, Anti-TG:
Anti-thyroglobulin antibody, AntiTPO: Anti-thyroid peroxidase antibody, CRP: C-reactive protein.
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(n = 23) of the patients in the malignant group and 73.5%
(n = 25) of the patients in the benign group were female.
There was no statistical difference between the benign and
malignant groups according to age and sex (p = 0.852; p
= 0.481, respectively). Thiol and disulphide parameters in
histopathologically benign and malignant patients and the
control group are shown in Table 4. There were statistically
significant differences in the disulphide/native thiol ratio
and disulphide/total thiol ratio between groups (p < 0.001
for all). Disulphide/total thiol and disulphide/native thiol
were significantly higher in the malignant compared to
the benign (p = 0.012; p = 0.007, respectively) and the
control groups (p = 0.006; p = 0.004, respectively), but no
significant difference was found between the benign and
the control groups (p = 0.711; p = 0.749, respectively).
4. Discussion
To our knowledge, this study is the first to compare
thiol/disulphide homeostasis in patients with euthyroid
nodular goiter and in healthy subjects. An increase in
free radicals is associated with alteration in protein
function, lipid denaturation, and structural damage to

DNA. These changes increase the risk of mutation and
neoplastic transformation [18,19]. B-Raf proto-oncogene
- Ras proto-oncogene point mutations and rearranged
during transfection (RET) gene fusions, which are the
most frequently activated oncogenes in papillary thyroid
cancer (PTC), activate the mitogen-activated protein
kinase (MAPK) signalling pathway. Oxidative stress is
considered a starting point for deoxyribonucleic acid
(DNA) damage which is the first step for tumorigenesis
[20]. It was shown that serum ischemia with modified
albumin (IMA) levels was increased in both hypothyroid
and hyperthyroid patients compared to euthyroid controls
in a metaanalysis [21]. Therefore, we excluded patients
with thyroid dysfunction (subclinical and overt) and
only included euthyroid patients in our study. A study
conducted in Turkey found that serum malondialdehyde
(MDA) level, which is a marker for lipid peroxidation,
was significantly higher in patients with euthyroid
multinodular goiter compared to the control group, and
it decreased after thyroidectomy [22]. In addition, it was
shown that MDA level is significantly higher in papillary
carcinoma samples than in normal thyroid tissue [23]. In

Table 2. Thiol/disulphide homeostasis in different Bethesda categories.

Variables

Non diagnostic Benign
(n = 23)
(n = 17)

AUS/FLUS
(n = 20)

FN/SFN
(n = 5)

SM
(n = 8)

Malign
(n = 8)

p value

Native Thiol
(μmol/L)

461.25 ± 57.61

453.57 ±64.87

470.20±63.57

415.40± 53.18

435.02±69.33

425.35±56.65

0.322

Total thiol
(μmol/L)

494.40 ± 59.20

490.72 ± 76.19

504.31 ± 63.09

472.76 ± 52.59

472.22 ± 79.16

459.6 ± 57.67

0.552

Disulphide
(μmol/L)

17.94 ± 9.69

16.49 ± 7.50

17.55 ± 7.14

24.68 ± 8.18

24.59 ± 7.7

25.37 ± 9.07

0.655

Disulphide/
3.97 ± 2.28
Native thiol (%)

3.75 ± 1.81

3.83 ± 1.65

6.39 ± 5.71

5.81 ± 2.20

6.15 ± 2.64

0.251

Disulphide/
Total thiol (%)

3.62 ± 1.90

3.43 ± 1.60

3.52 ± 1.43

5.28 ± 4.14

5.37 ± 2.11

5.60 ± 2.14

0.253

Native thiol/
Total thiol (%)

93.30 ± 4.05

92.58 ± 3.46

93.17 ± 3.09

87.97 ± 7.87

92.25 ± 2.77

92.62 ± 5.30

0.405

AUS/FLUS: Atypia of undetermined significance/follicular lesion of undetermined significance, FN/SFN: Follicular neoplasia /
suspicious for follicular neoplasia, SM: Suspicious for malignancy.

Table 3. Correlation between Bethesda categories with increasing risk of malignancy and thiol/disulphide homeostasis.
Variables

Disulphide

Native thiol

Total thiol

Disulphide/ native thiol Disulphide/ Total thiol Native thiol/ total thiol

Bethesda
r
p

0.281
0.011

–0.122
0.276

–0.073
0.516

0.241
0.030

0.250
0.024

–0.002
0.986
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Table 4. Comparison of thiol/disulphide homeostasis in histopathologically benign and malignant patients and
control group.
Variables

Benign (n = 34)

Malignant (n = 35)

Control (n = 28)

p

Native Thiol (μmol/L)

453.19 ± 63.49

457.47 ± 62.38

444.81 ± 71.9

0.477

Total thiol (μmol/L)

487.45 ± 67.87

497.09 ± 64.78

474.61 ± 75.48

0.256

Disulphide (μmol/L)

16.07 ± 9.28

19.85 ± 11.28

14.87 ± 7.62

0.191

Disulphide/native thiol (%)

3.58 ± 2.07

5.50 ± 2.85

3.41 ± 1.70

0.002a

Disulphide/total thiol (%)

3.27 ± 1.80

4.96 ± 2.24

3.15 ± 1.48

0.001b

Native thiol/total thiol (%)

93.01 ± 3.96

92.07 ± 4.73

93.74 ± 3.09

0.473

Significance between the malignant group and the benign group (p = 0.012) and the malignant group and the
control group (p = 0.006) (pairwise comparison).
b
Significance between the malignant group and the benign group (p = 0.007) and the malignant group and the
control group (p = 0.004) (pairwise comparison).
a

our study, preoperative disulphide/native thiol ratio and
disulphide/total thiol ratio were significantly higher in
patients with malignant histopathology compared to the
patients with benign histopathology and control group,
while no significant differences were observed between
the benign group and the control group. Wang et al.
reported that oxidative stress index was a determining risk
factor in patients with thyroid cancer than benign nodular
goiter and healthy control group [24]. In another study,
significantly higher free radicals were shown in tumour
thyroid tissue than the healthy thyroid tissue [25]. In a
study conducted in Turkey evaluating thiol/disulphide
homeostasis; native thiol and total thiol were lower, while
disulphide was higher in patients with thyroid cancer than
in the control group (n = 23) [26]. However, statistical
data were not provided in that study, probably because
the number of patients was not sufficient for statistical
analysis. Again, in a study from Turkey, superoxide
dismutase (SOD) was lower in various thyroid disorders,
including thyroid cancer [27]. The relevant literature,
including our study, suggests that oxidative stress markers
analysed with different methods are increased in patients
with thyroid cancer. In the study by Erel and Neselioğlu,
the most striking feature of thiol/disulphide balance is
that the analysis was performed by removing sodium
borohydride using formaldehyde [6]. We believe that we
reflected the thiol/disulphide homeostatic state better
than previous studies since the two elements could have
been measured separately with our method.
It has been suggested that the causes of the increase
in oxidative stress in thyroid cancer are the increased
lipid peroxidation and damage to the antioxidant
defence system [28]. Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases (Dual oxidase 1, Dual
oxidase 2, NADPH oxidase 4) are expressed in the human
thyroid gland and function as sources of ROS, suggesting
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that they may play a role in the pathogenesis of thyroid
diseases [29]. The direct interaction of ROS with DNA may
lead to oxidative DNA damage, including abasic regions
and single-stranded DNA breaks [30]. ROS sources in
thyroid tumour formation have been identified as dual
oxidase 1 and NADPH oxidase 4. The dysregulation
of their expression and activity may jeopardize DNA
stability and affect cell fate [29]. Chemical modifications
of the DNA structure, such as the presence of 8-oxo-2′deoxyguanosine as induced by oxidative stress, have been
found specifically in thyroid cancer [31].
According to the Bethesda scoring, the thiol/
disulphide homeostasis has not been previously
evaluated. Our study is the first attempt in that regard.
Malignancy risks in different Bethesda categories are
predicted as follows; nondiagnostic <1%–4%, benign
<1%, AUS/FLUS 5%–10%, FN/SFN 20%–30%, SM 60%–
75%, and malignant cytology 97%–99% [3]. In our study,
no significant difference was found between Bethesda
categories in terms of thiol-disulphide homeostasis.
However, disulphide/native thiol ratio (r = 0.241, p =
0.030) and the disulphide/total thiol ratio (r = 0.250,
p = 0.024) were positively correlated with Bethesda
categories with increasing malignancy risk. We think that
oxidative stress marker analysis in Bethesda subgroups
can be employed in a further study with a larger patient
population to enlighten this issue. Clarification of this
situation in the euthyroid multinodular patient group
may benefit many cases.
In conclusion, preoperative disulphide/native thiol
and disulphide/total thiol markers reflecting the oxidative
damage were significantly higher in the malignant group
compared to the benign and control groups. Bethesda
classification with increasing risk of malignancy was
positively correlated with disulphide/native thiol and the
disulphide/total thiol.

BİLGİNER et al. / Turk J Med Sci
5. Limitations
The main limitation of this study is its single-centred design
which makes it difficult to generalize the study results.
Secondly, no comparison was made with other oxidative
stress markers such as MDA and SOD because they were
not included in the analysis. Thirdly, there were relatively
few patients in the Bethesda subgroups, which might
have caused no difference in oxidative stress between the
Bethesda categories. Examining the relationship between
Bethesda categories and thiol/disulphide homeostasis in
a single Bethesda group with a larger patient population
may be more informative.
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